1
|
Short NJ, Rytting ME and Cortes JE: Acute
myeloid leukaemia. Lancet. 392:593–606. 2018. View Article : Google Scholar : PubMed/NCBI
|
2
|
Estey E and Döhner H: Acute myeloid
leukaemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar : PubMed/NCBI
|
3
|
Paschka P, Schlenk RF, Gaidzik VI, Habdank
M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K,
et al: IDH1 and IDH2 mutations are frequent genetic alterations in
acute myeloid leukemia and confer adverse prognosis in
cytogenetically normal acute myeloid leukemia with NPM1 mutation
without FLT3 internal tandem duplication. J Clin Oncol.
28:3636–3643. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Dang L, Yen K and Attar EC: IDH mutations
in cancer and progress toward development of targeted therapeutics.
Ann Oncol. 27:599–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Shih AH, Meydan C, Shank K,
Garrett-Bakelman FE, Ward PS, Intlekofer AM, Nazir A, Stein EM,
Knapp K, Glass J, et al: Combination targeted therapy to disrupt
aberrant oncogenic signaling and reverse epigenetic dysfunction in
IDH2- and TET2-mutant acute myeloid leukemia. Cancer Discov.
7:494–505. 2017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Green CL, Evans CM, Zhao L, Hills RK,
Burnett AK, Linch DC and Gale RE: The prognostic significance of
IDH2 mutations in AML depends on the location of the mutation.
Blood. 118:409–412. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
DiNardo CD, Ravandi F, Agresta S,
Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Mark
Brandt, Pierce S, et al: Characteristics, clinical outcome, and
prognostic significance of IDH mutations in AML. Am J Hematol.
90:732–736. 2015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Chao HY, Jia ZX, Chen T, Lu XZ, Cen L,
Xiao R, Jiang NK, Ying JH, Zhou M and Zhang R: IDH2 mutations are
frequent in Chinese patients with acute myeloid leukemia and
associated with NPM1 mutations and FAB-M2 subtype. Int J Lab
Hematol. 34:502–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Wiseman DH, Williams EL, Wilks DP, Sun
Leong H, Somerville TD, Dennis MW, Struys EA, Bakkali A, Salomons
GS and Somervaille TC: Frequent reconstitution of IDH2(R140Q)
mutant clonal multilineage hematopoiesis following chemotherapy for
acute myeloid leukemia. Leukemia. 30:1946–1950. 2016. View Article : Google Scholar : PubMed/NCBI
|
10
|
Huang R, Liao X and Li Q: Identification
of key pathways and genes in TP53 mutation acute myeloid leukemia:
Evidence from bioinformatics analysis. OncoTargets Ther.
11:163–173. 2017. View Article : Google Scholar
|
11
|
Huang R, Liao X and Li Q: Identification
and validation of potential prognostic gene biomarkers for
predicting survival in patients with acute myeloid leukemia.
OncoTargets Ther. 10:5243–5254. 2017. View Article : Google Scholar
|
12
|
Ley TJ, Miller C, Ding L, Raphael BJ,
Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty
JD, et al Cancer Genome Atlas Research Network, : Genomic and
epigenomic landscapes of adult de novo acute myeloid leukemia. N
Engl J Med. 368:2059–2074. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A Bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
16
|
McCarthy DJ, Chen Y and Smyth GK:
Differential expression analysis of multifactor RNA-Seq experiments
with respect to biological variation. Nucleic Acids Res.
40:4288–4297. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Liao X, Yang C, Huang R, Han C, Yu T,
Huang K, Liu X, Yu L, Zhu G, Su H, et al: Identification of
potential prognostic long non-coding rna biomarkers for predicting
survival in patients with hepatocellular carcinoma. Cell Physiol
Biochem. 48:1854–1869. 2018. View Article : Google Scholar : PubMed/NCBI
|
18
|
Wei HT, Guo EN, Liao XW, Chen LS, Wang JL,
Ni M and Liang C: Genome-scale analysis to identify potential
prognostic microRNA biomarkers for predicting overall survival in
patients with colon adenocarcinoma. Oncol Rep. 40:1947–1958.
2018.PubMed/NCBI
|
19
|
Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
20
|
Jiao X, Sherman BT, Huang W, Stephens R,
Baseler MW, Lane HC and Lempicki RA: DAVID-WS: A stateful web
service to facilitate gene/protein list analysis. Bioinformatics.
28:1805–1806. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Maere S, Heymans K and Kuiper M: BiNGO: A
Cytoscape plugin to assess overrepresentation of gene ontology
categories in biological networks. Bioinformatics. 21:3448–3449.
2005. View Article : Google Scholar : PubMed/NCBI
|
22
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45(D1): D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
24
|
von Mering C, Jensen LJ, Snel B, Hooper
SD, Krupp M, Foglierini M, Jouffre N, Huynen MA and Bork P: STRING:
Known and predicted protein-protein associations, integrated and
transferred across organisms. Nucleic Acids Res. 33:D433–D437.
2005. View Article : Google Scholar : PubMed/NCBI
|
25
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
et al: The GeneMANIA prediction server: Biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38 (Suppl 2):W214–W220. 2010. View Article : Google Scholar : PubMed/NCBI
|
26
|
Mostafavi S, Ray D, Warde-Farley D,
Grouios C and Morris Q: GeneMANIA: A real-time multiple association
network integration algorithm for predicting gene function. Genome
Biol. 9 (Suppl 1):S42008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Lamb J, Crawford ED, Peck D, Modell JW,
Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et
al: The Connectivity Map: Using gene-expression signatures to
connect small molecules, genes, and disease. Science.
313:1929–1935. 2006. View Article : Google Scholar : PubMed/NCBI
|
28
|
Lamb J: The Connectivity Map: A new tool
for biomedical research. Nat Rev Cancer. 7:54–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
29
|
Kim S, Thiessen PA, Bolton EE, Chen J, Fu
G, Gindulyte A, Han L, He J, He S, Shoemaker BA, et al: PubChem
substance and compound databases. Nucleic Acids Res.
44:D1202–D1213. 2016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Wang Y, Bryant SH, Cheng T, Wang J,
Gindulyte A, Shoemaker BA, Thiessen PA, He S and Zhang J: PubChem
BioAssay: 2017 update. Nucleic Acids Res. 45:D955–D963. 2017.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Kuhn M, von Mering C, Campillos M, Jensen
LJ and Bork P: STITCH: Interaction networks of chemicals and
proteins. Nucleic Acids Res. 36:D684–D688. 2008. View Article : Google Scholar : PubMed/NCBI
|
32
|
Kuhn M, Szklarczyk D, Franceschini A,
Campillos M, von Mering C, Jensen LJ, Beyer A and Bork P: STITCH 2:
An interaction network database for small molecules and proteins.
Nucleic Acids Res. 38 (Suppl 1):D552–D556. 2010. View Article : Google Scholar : PubMed/NCBI
|
33
|
Szklarczyk D, Santos A, von Mering C,
Jensen LJ, Bork P and Kuhn M: STITCH 5: Augmenting protein-chemical
interaction networks with tissue and affinity data. Nucleic Acids
Res. 44:D380–D384. 2016. View Article : Google Scholar : PubMed/NCBI
|
34
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J R Stat Soc Series B Stat Methodol. 57:289–300.
1995.
|
35
|
Reiner A, Yekutieli D and Benjamini Y:
Identifying differentially expressed genes using false discovery
rate controlling procedures. Bioinformatics. 19:368–375. 2003.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Benjamini Y, Drai D, Elmer G, Kafkafi N
and Golani I: Controlling the false discovery rate in behavior
genetics research. Behav Brain Res. 125:279–284. 2001. View Article : Google Scholar : PubMed/NCBI
|
37
|
Ahmad F, Mohota R, Sanap S, Mandava S and
Das BR: Molecular evaluation of DNMT3A and IDH1/2 gene mutation:
Frequency, distribution pattern and associations with additional
molecular markers in normal karyotype Indian acute myeloid leukemia
patients. Asian Pac J Cancer Prev. 15:1247–1253. 2014. View Article : Google Scholar : PubMed/NCBI
|
38
|
Lee CY, Tien HF, Hu CY, Chou WC and Lin
LI: Marrow angiogenesis-associated factors as prognostic biomarkers
in patients with acute myelogenous leukaemia. Br J Cancer.
97:877–882. 2007. View Article : Google Scholar : PubMed/NCBI
|
39
|
Trujillo A, McGee C and Cogle CR:
Angiogenesis in acute myeloid leukemia and opportunities for novel
therapies. J Oncol. 2012:1286082012. View Article : Google Scholar : PubMed/NCBI
|
40
|
Hussong JW, Rodgers GM and Shami PJ:
Evidence of increased angiogenesis in patients with acute myeloid
leukemia. Blood. 95:309–313. 2000.PubMed/NCBI
|
41
|
Krell D, Mulholland P, Frampton AE, Krell
J, Stebbing J and Bardella C: IDH mutations in tumorigenesis and
their potential role as novel therapeutic targets. Future Oncol.
9:1923–1935. 2013. View Article : Google Scholar : PubMed/NCBI
|
42
|
Schaap FG, French PJ and Bovée JV:
Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in
tumors. Adv Anat Pathol. 20:32–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
43
|
Bluteau D, Glembotsky AC, Raimbault A,
Balayn N, Gilles L, Rameau P, Nurden P, Alessi MC, Debili N,
Vainchenker W, et al: Dysmegakaryopoiesis of FPD/AML pedigrees with
constitutional RUNX1 mutations is linked to myosin II deregulated
expression. Blood. 120:2708–2718. 2012. View Article : Google Scholar : PubMed/NCBI
|
44
|
Okuda T, Nishimura M, Nakao M and Fujita
Y: RUNX1/AML1: A central player in hematopoiesis. Int J Hematol.
74:252–257. 2001. View Article : Google Scholar : PubMed/NCBI
|
45
|
Zhang F, Yang B, Zhang K, Hou ML, Lu XC
and Li YX: CCND1-BCL2 Gene Network: A direct target of Amifostine
in human acute megakaryocytic leukemia cells. Chem Biol Drug Des.
89:681–693. 2017. View Article : Google Scholar : PubMed/NCBI
|
46
|
Park IK, Mishra A, Chandler J, Whitman SP,
Marcucci G and Caligiuri MA: Inhibition of the receptor tyrosine
kinase Axl impedes activation of the FLT3 internal tandem
duplication in human acute myeloid leukemia: Implications for Axl
as a potential therapeutic target. Blood. 121:2064–2073. 2013.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Janning M, Ben-Batalla I and Loges S: Axl
inhibition: A potential road to a novel acute myeloid leukemia
therapy? Expert Rev Hematol. 8:135–138. 2015. View Article : Google Scholar : PubMed/NCBI
|
48
|
Ben-Batalla I, Schultze A, Wroblewski M,
Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D,
Sawall S, et al: Axl, a prognostic and therapeutic target in acute
myeloid leukemia mediates paracrine crosstalk of leukemia cells
with bone marrow stroma. Blood. 122:2443–2452. 2013. View Article : Google Scholar : PubMed/NCBI
|
49
|
Flotho C, Paulun A, Batz C and Niemeyer
CM: AKAP12, a gene with tumour suppressor properties, is a target
of promoter DNA methylation in childhood myeloid malignancies. Br J
Haematol. 138:644–650. 2007. View Article : Google Scholar : PubMed/NCBI
|
50
|
Yoshida K, Sanada M, Shiraishi Y, Nowak D,
Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, et
al: Frequent pathway mutations of splicing machinery in
myelodysplasia. Nature. 478:64–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
51
|
Larsson CA, Cote G and Quintás-Cardama A:
The changing mutational landscape of acute myeloid leukemia and
myelodysplastic syndrome. Mol Cancer Res. 11:815–827. 2013.
View Article : Google Scholar : PubMed/NCBI
|
52
|
Sauter C, Fehr J, Frick P, Gmuer J,
Honegger H and Martz G: Acute myelogenous leukemia: Successful
treatment of relapse with cytosine arabinoside, VP 16–213,
vincristine and vinblastine (A-triple-V). Eur J Cancer Clin Oncol.
18:733–737. 1982. View Article : Google Scholar : PubMed/NCBI
|
53
|
Müller MR, Sauter C, Erni J and Martz G:
Influence of a new relapse treatment for acute myeloid leukemia
(AML) on in vitro granulopoiesis. Anticancer Res. 3:127–131.
1983.PubMed/NCBI
|
54
|
Chau CH, Price DK, Till C, Goodman PJ,
Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, et
al: Finasteride concentrations and prostate cancer risk: Results
from the Prostate Cancer Prevention Trial. PLoS One.
10:e01266722015. View Article : Google Scholar : PubMed/NCBI
|
55
|
Moroz A, Delella FK, Almeida R, Lacorte
LM, Fávaro WJ, Deffune E and Felisbino SL: Finasteride inhibits
human prostate cancer cell invasion through MMP2 and MMP9
downregulation. PLoS One. 8:e847572013. View Article : Google Scholar : PubMed/NCBI
|
56
|
Wiebe JP, Rivas MA, Mercogliano MF,
Elizalde PV and Schillaci R: Progesterone-induced stimulation of
mammary tumorigenesis is due to the progesterone metabolite,
5α-dihydroprogesterone (5αP) and can be suppressed by the
5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol.
149:27–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
57
|
Seo JO, Yumnam S, Jeong KW and Kim SY:
Finasteride inhibits melanogenesis through regulation of the
adenylate cyclase in melanocytes and melanoma cells. Arch Pharm
Res. 41:324–332. 2018. View Article : Google Scholar : PubMed/NCBI
|